These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16282089)

  • 21. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey.
    Nunn A; Zaller N; Dickman S; Trimbur C; Nijhawan A; Rich JD
    Drug Alcohol Depend; 2009 Nov; 105(1-2):83-8. PubMed ID: 19625142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The implications of medication development in the treatment of substance use disorders in developing countries.
    Thirthalli J; Chand PK
    Curr Opin Psychiatry; 2009 May; 22(3):274-80. PubMed ID: 19346946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How do treatment repeaters use the drug treatment system? An analysis of injection drug users in Massachusetts.
    Lundgren LM; Sullivan L; Amodeo M
    J Subst Abuse Treat; 2006 Mar; 30(2):121-8. PubMed ID: 16490675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of drug use during imprisonment: relationship of drug type, recency of use and severity of dependence to use of heroin, cocaine and amphetamine in prison.
    Strang J; Gossop M; Heuston J; Green J; Whiteley C; Maden A
    Addiction; 2006 Aug; 101(8):1125-32. PubMed ID: 16869842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New challenges and opportunities in managing substance abuse in Malaysia.
    Mazlan M; Schottenfeld RS; Chawarski MC
    Drug Alcohol Rev; 2006 Sep; 25(5):473-8. PubMed ID: 16939945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological treatments for substance use disorders.
    Bailey KP
    J Psychosoc Nurs Ment Health Serv; 2004 Aug; 42(8):14-20. PubMed ID: 15354595
    [No Abstract]   [Full Text] [Related]  

  • 27. [Value of drug screening in granting leave of absence to prisoners].
    Lapornik R; Zapotoczky HG
    Wien Klin Wochenschr; 1998 Nov; 110(21):755-8. PubMed ID: 9871967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of therapeutic engagement in prison-based drug treatment.
    Welsh WN; McGrain PN
    Drug Alcohol Depend; 2008 Aug; 96(3):271-80. PubMed ID: 18486361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.
    O'Malley SS; Sinha R; Grilo CM; Capone C; Farren CK; McKee SA; Rounsaville BJ; Wu R
    Alcohol Clin Exp Res; 2007 Apr; 31(4):625-34. PubMed ID: 17374042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches.
    Green AI
    J Clin Psychiatry; 2006; 67 Suppl 7():31-5; quiz 36-7. PubMed ID: 16961422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Narcotic antagonists: naltrexone progress report: foreword.
    Jaffe J
    NIDA Res Monogr; 1976 Sep; (9):v-vii. PubMed ID: 1088898
    [No Abstract]   [Full Text] [Related]  

  • 32. Substance use in remand prisoners: a consecutive case study.
    Mason D; Birmingham L; Grubin D
    BMJ; 1997 Jul; 315(7099):18-21. PubMed ID: 9233320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
    Haile CN; Kosten TA; Kosten TR
    Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Narcotic antagonists in the treatment of opioid dependence: review and commentary.
    Resnick RB; Schuyten-Resnick E; Washton AM
    Compr Psychiatry; 1979; 20(2):116-25. PubMed ID: 421447
    [No Abstract]   [Full Text] [Related]  

  • 36. Naltrexone for probationers and parolees.
    O'Brien C; Cornish JW
    J Subst Abuse Treat; 2006 Sep; 31(2):107-11. PubMed ID: 16919734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A history of the development of narcotic antagonists for the treatment of narcotic addiction.
    Martin WR
    NIDA Res Monogr; 1978; (19):296-300. PubMed ID: 218106
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug use and mental health problems among prison inmates--results from a nation-wide prison population study.
    Friestad C; Kjelsberg E
    Nord J Psychiatry; 2009; 63(3):237-45. PubMed ID: 19034714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does naltrexone affect craving in abstinent opioid-dependent patients?
    Dijkstra BA; De Jong CA; Bluschke SM; Krabbe PF; van der Staak CP
    Addict Biol; 2007 Jun; 12(2):176-82. PubMed ID: 17508990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A clear look].
    Vasseur V
    Ann Med Interne (Paris); 2000 Oct; 151 Suppl B():B4. PubMed ID: 11104936
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.